schizophrenia

Jan 19 2025

Uncategorized

Boehringer’s phase 3 schizophrenia program misses primary goal – Fierce Biotech

by Clinical Editor

No Comments

Boehringer’s phase 3 schizophrenia program misses primary goal  Fierce Biotech

Jan 19 2025

Uncategorized

Immune system changes may predict antipsychotic resistance in schizophrenia Scientis…

by Clinical Editor

No Comments

Researchers from the National Healthcare Group (NHG)’s Institute of Mental Health (IMH) and Agency for Science, Technology and Research (A*STAR) have made strides in understanding the connection …

Jan 18 2025

Uncategorized

Novel Therapy Linked to Cognitive Benefit in Schizophrenia – Medscape

by Clinical Editor

No Comments

Novel Therapy Linked to Cognitive Benefit in Schizophrenia  Medscape

Jan 18 2025

Uncategorized

Pandemic led to rapid adoption of telemental health for those with schizophrenia

by Clinical Editor

No Comments

For Medicaid beneficiaries with schizophrenia, delivery of mental health care through telehealth (telemental health care) diffused rapidly after onset of the COVID-19 pandemic, according to a study …

Jan 17 2025

Uncategorized

Boehringer drug for brain fog in schizophrenia fails trial

by Clinical Editor

No Comments

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, bringing to an end what it said was the largest programme...

Jan 17 2025

Uncategorized

Novel Therapy Linked to Cognitive Benefit in Schizophrenia

by Clinical Editor

No Comments

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, independent of symptom changes, new research suggested.

Jan 16 2025

Uncategorized

Clayton Co. police looking for missing 17-year-old boy with schizophrenia, bipolar disorder – WSB Atlanta

by Clinical Editor

No Comments

Clayton Co. police looking for missing 17-year-old boy with schizophrenia, bipolar disorder  WSB Atlanta

Jan 16 2025

Uncategorized

Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug

by Clinical Editor

No Comments

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.

Jan 15 2025

Uncategorized

Bristol Myers Says New Schizophrenia Drug Off to Strong Start – Bloomberg

by Clinical Editor

No Comments

Bristol Myers Says New Schizophrenia Drug Off to Strong Start  Bloomberg

Jan 15 2025

Uncategorized

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

by Clinical Editor

No Comments

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of...